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Abstract 
 
Amylase was the first enzyme to be characterised, and for the past 200 years, its clinical role was 
restricted to a diagnostic aid. Recent interface research has led to a substantial expansion of its role into 
novel, viable diagnostic and therapeutic applications to cancer, infection, and wound healing. This 
review provides a concise “state of the art” overview of the genetics, structure, distribution, and 
localisation of amylase in humans. To the four classical hyperamylasemia patterns (pancreatic, salivary, 
macroamylasemia, and combinations) a fifth, the localised targeting of amylase to specific foci of 
inflammation is proposed. The implications are directed at novel therapeutic and diagnostic clinical 
applications of amylase such as the novel therapeutic drug classes capable of targeted delivery and 
“smart release” in areas of clinical need. Future directions of research in areas of high clinical benefit are 
reported. 
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1. Introduction 
Infection, cancer impaired wound healing continue to present formidable challenges to the current 
practice of surgery.1-4 Combined, these represent the main cause of mortality, morbidity and recurrent 
health expenditure worldwide.5 Additionally, the disproportionate increase in multidrug resistant 
infection against the decline in development of novel antibiotics has been recognised as a global threat 
in many areas of medicine and surgery.6-8 Therefore, novel developments with the potential to improve 
diagnostics and therapeutics across all three fields are highly sought after. 
 
Amylase was the first enzyme to be discovered and isolated by Payen in 1833.9, 10 Over the last 190 
years, its use in the diagnosis of pancreatic and associated diseases has been well-established.11 The last 
20 years have witnessed intensive research into expanding the clinical applications of this venerable 
enzyme with high relevance to surgical management, including the treatment of surgical infection, solid 
cancer, and wound management. This study provides a concise “state of the art” overview of advances 
in basic science concerning amylase structure, function, and bio-distribution, leading into clinically 
relevant diagnostic and therapeutic applications that have reached clinical practice or advanced stages 
of development. The review draws on advances at the interface of surgery, diagnostics, synthetic 
chemistry, and nanomedicine to indicate clinically valid directions for future research.  
 
2. Methods 
A first generation literature search was performed using the MeSH 12 search string  “Amylase AND 
(diagnost* OR therapeut$)” on the OVID-SP and PUBMED platforms. 1755 studies were retrieved and 
screened for relevance. A second generation search was then performed by forward and backward 
referencing on Web of Knowledge™ and manual indexing. Only articles with full text available in English 
were included.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
3. Literature Review 
3.1 Amylase Enzyme Classification 
Amylases are part of a large group of glycosyl hydrolase enzymes that catalyse the breakdown of 
complex carbohydrates.13, 14 Fifty seven families of glycosyl hydrolases have been classified based on 
their function and specificity 15 (Table 1). Of the three main classes of amylase enzymes (α, β and ɣ), α-
amylase is found in animals, plants, fungi, and bacteria, β amylase is found in plant seeds, bacteria and 
fungi and ɣ amylase is found in yeast and fungi. The main function of all of the amylases is to degrade 
starch and sugars. However, there is a difference in their structure and mode of action. α-amylase 
cleaves randomly along the starch chain and because of this non-specificity, digestion is more rapid than 
other amylases.16  
 
3.2 Human α-amylase: genetics and function-structure considerations 
Salivary α-amylase is expressed in salivary, mammary, and lacrimal glands, while the pancreatic isoform 
is only expressed in the pancreas.17 Pancreatic α-amylase constitutes 5-6% of the total protein present in 
pancreatic secretions, and unlike many other pancreatic enzymes, it has no inactive precursor.18 Gene 
structure suggests that the human salivary amylase gene has evolved from a pre-existing pancreatic 
amylase gene. Figure 1 reports the relationship between structure, function, and genetics of this 
enzyme family.  
 
3.3 Mode of action, cofactors, and clinically relevant substrates 
Current assays only measure activity, and therefore the mode of action, environmental conditions, 
presence of cofactors, and substrate nature merit consideration. Figure 2 illustrates that the mode of 
action of α-amylase is a double displacement mechanism. Human α-amylase requires two essential 
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cofactors for its activity: chloride and calcium ions.19 The α-amylases are calcium metalloenzymes and 
are unable to function in the absence of calcium.19 The calcium ion is coordinated between 8 ligands 
from the main amino acid chain, side chains, and three water molecules while the chloride ion binds 
closely to the active site and is considered to act as an allosteric activator. Several medical devices 
chelate calcium, possibly affecting amylase activity, for instance alginate dressings.20, 21 Several amylase 
inhibitors have been identified and used clinically in the treatment of human disease (Section 3.7). 
Whereas the physiologic pH range of blood is 7.35-7.45, the optimum pH for amylase activity is 6.7 to 
7.0, which would be expected in pathophysiologic states such as infection and possibly solid tumors.22 
Localised amylase concentrations are increasingly important in the development of amylase-based 
therapeutics (section 3.5). Such devices and medical dressings may also adversely affect the amylase 
assays in current use because they are activity, not concentration based (section 3.5).   
 
3.4 Distribution in Pathophysiologic States    
The classic diagnostic use of α-amylase presupposes that the plasma concentration of α-amylase reflects 
the pathophysiologic processes in the source organ, and increases in α-amylase activity in human serum 
has traditionally formed the basis of its clinical applicability. Four patterns of generalised 
hyperamylasemia have been recognized: pancreatic, salivary, macroamylasemia, and combinations 
thereof.19 Pancreatic and salivary disease are described extensively elsewhere.23 Macroamylasemia is 
the increase of serum α-amylase due to a macromolecular complex between amylase and 
immunoglobulins which imparts increased size and molecular weight. This benign biochemical 
aberration only affects approximately 0.4% of the general population.24-26 but can be a source of 
diagnostic confusion.27 Table 2 provides examples of clinical conditions associated with 
hyperamylasaemia. Additionally it is proposed that amylase can sequestrate locally at operative sites of 
enhanced vascular permeability or bacterial infection. 
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3.4.1 The Enhanced Permeability and Retention (EPR) Phenomenon 
The EPR effect is mediated by the enhanced vascular permeability and distorted/dysfunctional 
lymphatic drainage of macromolecules at sites of localized inflammation.28 Large molecules such as 
amylase may therefore be retained in areas of enhanced vascular permeability and distorted drainage 
such as infection. It has been recently proposed that the EPR effect is mediated by Bradykinin, resulting 
in localised hyperpermeability of the microvasculature. Based on this notion, novel bio responsive 
antibiotics have been described recently.2, 29, 30  Evidence of localisation of amylase to surgical site 
infection has been claimed from a consecutive series of patients (n=6) with infected burn wounds,31, 32 
but it is known that amylase is present in sweat. Interestingly, histamine has also been reported recently 
to stimulate secretion of pancreatic α-amylase into the gastrointestinal tract and increase vascular 
permeability.33-35  
 
3.4.2 Bacterial amylase 
Bacterial amylase is essential to the Bacillus and Clostridium genus.36-40 Such bacteria cannot absorb 
starches and therefore, α-amylase is constitutively secreted, digesting glucose which can then be 
absorbed.41 Interestingly, organisms in this genus are capable of prolific amylase secretion, and may 
consequently increase amylase levels around the infected site by several orders of magnitude.41-47 
Several organisms in these genuses are responsible for life-threatening human infection, often requiring 
urgent treatment including C. perfringens (gas gangrene), 48 C. tetanii (tetanus), 49 C. difficile (hospital 
acquired pseudomembranous colitis),50, 51 and B. cereus (food poisoning). Several Bacillus species are 
exploited in the alimentary biotechnology industry for their prolific amylase production.52, 53 Harnessing 
this phenomenon for clinical diagnostic and / or therapeutic applications, however, has not yet been 
reported. Additionally, Aeromonas hydrophila, a Gram negative pathogen, constitutively expresses 
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Dextrin and dextran are mentioned here as two salient examples. Dextrin is a α-1, 4 poly (D-glucose) 
polymer obtained from hydrolysis of starch. Dextrins are largely linear polymers with limited (< 5%) 
branching in the α-1, 6 position and have an established safety profile.63, 64 Dextrin's versatility to several 
clinical applications has been well-established. Dextrin is used as a supplement for renal and hepatic 
failure 65 as a carrier for intraperitoneal 5-fluorouracil, 66, 67 and as a component of peritoneal dialysis 
solutions. 68 In contrast, dextran is a complex, branched glucose polymer which consists of both α-1,6 
glycosidic linkages and branches at α-1,3 linkages.69 Dextran is used medicinally as an antithrombotic 
(antiplatelet) to decrease blood viscosity and as a volume expander in hypovolaemia.70 Amylase is the 
enzyme which provides a predictable, safe degradation of these polymers in the bloodstream, 
eventually resulting in hydrolysis to simple sugars that can be fully metabolised. In this regard, α-
amylase triggers hydrolysis of α-1,4 glycosidic linkages forming maltose and iso-maltose which are 
metabolised subsequently to glucose by tissue maltases, and/or excreted into urine.71-73 The importance 
of amylase in this context is often overlooked. Consequently, the effect of co-incidental disease that 
affects amylase levels, which may dictate the duration of the intended therapeutic effect, is often 
overlooked (Table 2).  
 
An extra level of complexity can be achieved if these polymers are combined chemically to bioactive, 
conventional molecules of interest. In fact amylase and its associated polymer substrates have been 
found to be of considerable interest within the field of polymer therapeutics and specifically the science 
of conjugating of large, water soluble polymers to bioactive molecules of interest.74, 75. Coupling a 
conventional medicinal to a polymer achieves macromolecular status with distinct therapeutic 
advantages.76-78 Polymer therapeutics has yielded some of the major pharmaceutical “block busters” of 
the past 10 years.74  
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Conjugation to a polymer “shields” the body from potential adverse effects of a payload, as well as the 
payload itself from being degraded, immunologically attacked, or cleared by the kidneys.79 Additionally, 
however, use of a biodegradable polymer with the appropriate enzyme would result in biodegradation 
and release of the active payload. In this strategy, the biodegradable polymer shields the payload while 
in transit. Macromolecular status imparts passive targeting of the drug through the EPR effect 31, 77, 80, 81 
allowing accumulation at a site of inflammation. The target enzyme present therein will degrade the 
polymer releasing the active compound. This approach is termed the Polymer Mask Unmask Protein 
Principle (PUMPT).82 
 
The rate of degradation of this polymer conjugated to a drug of choice can be predicted in vitro and ex 
vivo by custom-engineering the chain length of the polymer and the degree of pendant groups.76  
Amylase is an endogenously produced enzyme with multiple polymer substrates that happen to be 
already licensed for human use. PUMPT was in fact described using amylase and succinoylated dextrin 
as a proof of principle.81 The PUMPT approach has been described for several clinical applications.  
 
Hardwicke et al. used the biodegradable polysaccharide dextrin and a recombinant human epidermal 
growth factor (rhEGF) as a first in class proof of concept based on the premise that the conjugate would 
localise to the wound due to the EPR effect.83 In 2014, a prototype dextrin-colistin conjugate was 
customised by polymer modification and binding chemistry to afford selective, controlled release at an 
infected site was reported.84, 85 These studies employed the biodegradable, naturally-occurring polymer, 
dextrin, and different bioactive molecules. 82, 84, 86, 87  
 
While the EPR effect has been demonstrated to be highly successful in pre-clinical species it has been 
less successful clinically; therefore, additional levels of complexity to augment targeting have been 
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described.  One strategy is to add an antibody binding. Tilmanocept is one such example.  Tilmanocept is 
a recently described, mannosylated, dextran-based polymer therapeutic for sentinel lymph node 
imaging which may offer an innovative solution for patients with melanoma and breast cancer. It has 
been FDA approved and has not been associated to any of  adverse effects. Tilmanocept binds tightly to 
CD206 mannose receptors on the surface of reticuloendothelial cells resident in lymph nodes for up to 
30 h.88 In two rigorously conducted phase III trials, Tilmanocept identified correctly a significant 
proportion (an additional 20%) of melanoma-positive sentinel nodes that were not detected by blue 
dye.89 Complexity can also be achieved by loading many biological payloads onto a polyfunctional 
polymer,90 such as hydroxyethyl starch conjugation to hemoglobin.91 Of note, hydroxyethyl starch is a 
substrate of amylase, and was, until recently, used as a volume expander and carried an increased risk 
of renal dysfunction and mortality over a 90-day follow-up in patients who received HES compared with 
crystalloids.92 Increased mortality in patients with sepsis was also observed prompting their UK-wide 
recall.92, 93 It is likely, however, that these adverse effects would not be associated to the quantities 
administered for drug delivery, which are minute compared to those required for plasma volume 
expansion.  
 
 
The efficacy of such targeting techniques does, however, depend on the underlying principles being 
widespread phenomena, with sufficient magnitude of effect to allow clinical harnessing.81, 94. Several 
studies have focussed on producing novel bioresponsive classes of drugs based on polymer substrates of 
amylase, but no studies have proven conclusively that amylase actually localises at the site of interest. 
Application of the same technology to areas where first generation (non-biodegradable) polymer 
therapeutics have already reached the clinic may have wide-reaching implications for other aspects of 
surgery, including rheumatoid arthritis, sentinel lymph node identification, and breast cancer.75, 78  
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3.5.2 Other clinical therapeutic uses of amylases in surgery 
α-amylase is a component in several pharmaceutical enzyme replacement preparations, used to treat 
pancreatic insufficiency. For instance, due to the absence of the cystic fibrosis trans-membrane 
regulator (CTFR), the secretion of α-amylase is obstructed.95 This means patients with cystic fibrosis can 
be treated with enzyme replacement therapies to prevent malnutrition.96 Conversely, α-amylase 
inhibitors have been licensed for the treatment of type 2 diabetes. Acarbose, one such example, is a 
pseudotetrasaccharide from Actinoplanes spp. which works by binding to the active subsites -3 through 
to +2.97, 98  Similarly, phaseolamin has been marketed as an enteric amylase inhibitor adjunct to weight 
loss and is available as an over the counter drug. De Gouveia et al. found that patients treated with 
phaseolamin did not have any decrease in body weight, but this study was conducted for only 20 days 
and therefore, follow-up bias could have affected the conclusions of this study.99 The use of 
phaseolamine as an antihyperglycemic is contended. Oliveira et al. found that phaseolamin can be used 
to control diabetes due to its anti-hyperglycemic effect.100 Another study did not find any effect on the 
glycemic state, although this could be due to the low dose used in the latter study.101 Interestingly, the 
product of amylase activity (glucose) has been shown to inhibit effectively the production of the main 
toxins responsible for the onset and progression of gas gangrene, lending some credence to claims of 
antibacterial efficacy of sugar based wound dressings such as Manuka Hone.102 
 
3.5.3 Clinical Diagnostics  
Hitherto, the principal use of α-amylase remains in clinical diagnostics. The normal range of human 
serum α-amylase activity is 23-85 IU/L, however there is substantial inter-laboratory and inter-assay 
variation.86 Pancreatic α-amylase is produced exclusively by the pancreas which increases its specificity 
for the diagnosis of pancreatic diseases. Furthermore, detecting the activity of the pancreatic isoform 
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compared to the total amylase, increases the sensitivity, therefore differentiating between the two 
isoforms is important clinically.103, 104 Various methods to accomplish this differentiation have been 
described previously in literature, including enzyme-immunoassays and partial inhibition of salivary 
amylase by various different  inhibitors.104 Widespread clinical adoption of classic diagnostic and, more 
recent therapeutic and combined approaches using α-amylase are dependent on rapid, cost-effective, 
and real-time quantification of α-amylase activity. A detailed description of state of the art sensors 
under development or fully developed is provided in the supplementary material (online only). The 
methods of detection either depend on product formation or substrate degradation or antibody binding. 
Total α-amylase is used as an indication of pancreatic or salivary disease.  
 
The p-nitrophenol assay is directly proportional to α-amylase activity and is measured photometrically. 
The range of detection is 3-1500 IU/L. This assay is used widely in the National Health Service (in the 
United Kingdom), but it does not distinguish bacterial from human amylase.105 In contrast, antibody 
assays employ a human anti-α-amylase antibody as it will eliminate any false positives due to bacterial 
secretion of amylase, while also being sub-type specific.106 Commercially available assays all rely on 
measuring activity of α-amylase, while an antibody approach would quantify concentration of α-amylase 
(as opposed to amylase activity) with a high degree of sensitivity and specificity in control and patient 
samples. Aluoch et al. designed a novel amperometric biosensor using a salivary anti α-amylase antibody 
which is monitored by an electroactive indicator. This indicator is oxidized or reduced causing current 
change which gives analytic information on the concentration of amylase. Its limit of detection is 1.57 
pg/mL which is more sensitive than enzyme-linked immunosorbent assay (ELISA, 10 ng/mL).106 Although 
this study describes a simple design, silver precipitation can be a concern because it would lead to 
insensitivity, possibly limiting this approach to single use, and thereby markedly increasing cost. An 
experimental “online” in vivo sensor reported by Wu et al. uses starch immobilized on a magneto-elastic 
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sensor. In the presence of amylase, there is a decrease in mass loading resulting in an increase in 
resonance frequency; the device suffers currently from lack of sensitivity.107 Nonetheless, this study 
highlights the potential of rapid, “online” bedside amylase detection methods and offers substantial 
improvement including cost-effectiveness, and real time measurement. Wang et al. developed a 
protocol which uses a portable device to measure α-amylase concentration. The feasibility of point-of 
care monitors has been well-established in other clinical conditions such as diabetes.108 The 
methodology of Wu et al. however, requires the sample to be incubated for 15 minutes at 37oC for the 
reaction to occur, which limits the applicability of this method at the point of care, because the sample 
has to be processed using laboratory equipment before using the sensor. Given the direction of research 
into amylase as a trigger for several personalisable and therapeutics such as infection, cancer and 
wound healing, the literature reviewed in this section suggests that miniaturised, cost-effective, 
personal point-of-care biosensors for α-amylase would have potential advantages over current 
diagnostic approaches. By being able to record amylase activity at a personal, point of care level, such 
devices may increase the scope of amylase-based therapeutics, expand both diagnostic and therapeutic 
use into personalised medicine.  
4. Conclusion 
Novel amylase-based therapeutics and diagnostics have experienced a period of intensive research, 
resulting in novel technologies with substantial clinical potential. Clinically relevant classifications of 
hyperamylasemia presented in this study may help to direct the surgeon during the “surgical sieve” 
diagnostic process. Proof-of-concept for the EPR and the PUMPT phenomena may provide novel and 
bioresponsive “smart” approaches to the management of common surgical disease. These advances are 
based on interface research linking demand (clinical) to supply (basic sciences), providing novel and 
exciting solutions to surgical problems of global health concern, and it is, therefore, important for the 
practicing surgeon to be aware of progress in this field. The advent of portable point-of-care, amylase 
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sensing devices may facilitate surgical decision making and applicability of amylase-based polymer 
therapeutics. Further availability of ex vivo and clinical data to support the use of amylase-based 
therapeutics would support allow clinical harnessing, and stimulate further development of novel, 
effective drugs based on such principles.  
 
Abbreviations:  
PUMPT Polymer Mask Unmask Protein Therapy Principle. CAZy = carbohydrate-active enzymes; EPR: 
Enhanced permeability and retention; PUMPT = polymer mask-unmask protein therapy; CFTR = Cystic 
Fibrosis Transmembrane Regulator, HIV = Human Immunodeficiency Virus, MetS = Metabolic syndrome; 
AMP = Amperometric, EIS = Electrochemical Impedance Spectroscopy, FAU = Fungal Amylase Unit, FIA = 
Flow Injection Analysis, KNU = kilo Novo unit, LOD = Limit of Detection, LR = Linear Range, nkat = 
nanokatals. 
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Figure Legend 
Figure 1: Systematic representation of the structure of human α-amylase (a) Amino acid sequence of 
human α-amylase indicating the binding sites for calcium (orange arrows), chloride (black arrows) and N-
glycosylation sites (blue arrows) (b) Active site is a V-shaped cleft subdivided into different sub-sites, 
glycone, individual sugar residues in a oligosaccharide chain (-4,-3,-2 and -1) and aglycone, individual 
sugar residues after hydrolysis of glycosidic bond (+1, +2 and +3). Each sub-site interacts with a 
monosaccharide, and cleavage occurs between +1 and -1, shown in the figure by the orange line. 
 
Figure 2: Systematic representation for the hydrolysis of glycosidic linkages by amylase. (a) The first 
displacement mechanism. The acid group of α-amylase reacts with the glyosidic oxygen to form an 
oxcarbenium ion-like transition state. This goes through nucleophilic attach by the acid of α-amylase to 
give a β-glycosyl enzyme intermediate. (b) The β-glycosyl enzyme intermediate reacts with activated 
H2O which forms an oxcarbenium ion-like transition state. The acid group of α-amylase is then 
reprotonated. Most forms of α-amylase are endo-enzymes, acting on substrate bonds within the 
carbohydrate chains, rather than those at the terminal ends. In contrast, maltogenic amylase is an 
exoenzyme subclass which hydrolyses terminal end residues which lead to them being re-classified as 
maltogenic amylases.  
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Figure 1: Systematic representation of the structure of human α-amylase (a) Amino acid sequence of 
human α-amylase indicating the binding sites for Calcium (orange arrows), Chloride (black arrows) and 
N-glycosylation sites (blue arrows) (b) Active site is a V-shaped cleft subdivided into different sub-sites, 
glycone, individual sugar residues in a oligosaccharide chain (-4,-3,-2 and -1) and aglycone, individual 
sugar residues after hydrolysis of glycosidic bond (+1, +2 and +3). Each sub-site interacts with a 
monosaccharide and cleavage occurs between +1 and -1, shown in the figure by the orange line. (C) 
Important difference from human pancreatic to salivary amylase are listed herein.  
Number of 
Genes 
Two pancreatic α-amylase genes and one salivary α-amylase gene, at 
chromosome 1p21. 
109
 
Evolution Salivary amylase gene has evolved from a pre-existing pancreatic amylase gene. 
The alteration in tissue specificity is probably due to retroviral insertion upstream 
of the amylase gene  
109
 
Domain 
structure 
Domain A (residues 1-99, 170-404) has an eight-stranded parallel β-barrels in the 
centre of α-helical segments. This αβ architecture forms different subsites of the 
active site (Figure 1b.). Domain B (100-168) forms a large loop between the third 
β-strand and the α-helix. Domain C (405-496) consists of a β-stranded structure 
(Figure 1a.)  
19, 110, 111
   
Homology  Salivary and pancreatic α-amylase have 97% homology with each other. A total of 
15 individual amino acid substitutions result in three more polar groups and three 
side chains to the salivary amylase 
19, 110
 
Functional 
significance 
Six of these individual substitutions are between residues 340-404 which is within 
the amino acid sequence that connects the A domain and C domain.  
19
 
Clinical 
application 
Two of these substitutions Thr 163 Ser and Leu 196 Ile have a direct effect on 
substrate binding, and different specificities to length of polysaccharides.  
19
 
Post 
translational 
modifications 
In pancreatic α-amylase, a carbon atom on the side chain of the terminal 
glutamine residue and increases stability by providing protection against amino 
peptidases. This post-translational modification appears to be specific to 
pancreatic (as opposed to salivary) amylase. 
19
 
N-glycosylation sites (Asn 427 and 
Asn 476) 
Cl- binding sites (Asn 298 and Arg 337) 
Domain A Domain B  Domain A  
 
 
Domain C 
Scale from 0 amino acids to 500 
amino acids 
Ca2+ binding sites (Asn 100 and 
Arg 158, Asp 167 and His 201) 
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Figure 2: Schematic representation for the hydrolysis of glycosidic linkages by amylase. (a) The first 
displacement mechanism. The acid group of α-amylase reacts with the glyosidic oxygen to form an 
oxcarbenium ion-like transition state. This goes through nucleophilic attach by the acid of α-amylase to 
give a β-glycosyl enzyme intermediate. (b) The β-glycosyl enzyme intermediate reacts with activated 
H2O which forms an oxcarbenium ion-like transition state. The acid group of α-amylase is then 
reprotonated. Most forms of α-amylase are endo-enzymes, acting on substrate bonds within the 
(a) 
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carbohydrate chains, rather than those at the terminal ends. In contrast, maltogenic amylase is an 
exoenzyme subclass which hydrolyses terminal end residues which lead to them being re-classified as 
maltogenic amylases.   
 
Tables 
Table 1: Current classifications of Amylolytic Enzymes   
Subtheme Current Trends in Literature 
Homology  Minimal amino acid sequence homology but high homology in polypeptide 
folding. Example: α-amylase very similar active site centred around three 
conserved carboxylate groups. Four segments with of sequence with good 
homology; 96-101, 193-201, 233-236 and 294-301.
112, 113
 
Classification method IUB method does not take into account evolutionary events. Amylolytic enzymes 
characterized on amino acid sequence homology, reaction mechanism, three 
dimensional structure and active sites.
15, 16
  
Number of families 1991 found 35 different glycoside hydrolase families looking at sequence 
homology 
15
. Over 950 glycosyl hydrolases have been sequenced 
113-115
 to date. 
Family similarities  Three dimensional structure suggests that families may be related to each other. 
For example, families 19, 22, 23 and 24.
115
 
CAZy database Contains family divisions based on amino acid sequence of all CAZymes. In 2009, 
the database covered 300 protein families including glycosyltransferases, 
polysaccharide lyases and glycoside hydrolase.
116
 In 2013, there were 330 
families and over 340000 CAZymes with sequence information.
117
 α-amylase falls 
into the glycoside hydrolase family 13 
110
.  
CAZy = carbohydrate-active enZymes 
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Table 2: Pathophysiological states affecting plasma amylase levels other than pancreatic and salivary 
 
Disease  α-amylase activity Study 
Diabetes Mellitus 
 
A study of 9340 diabetics 1102 (11.8%) had elevated α-amylase of that, 22.3 
(4.1 %) had abnormal renal function. 
 
118
 
 
Sjögren’s Syndrome 24% of patients with Sjögren’s syndrome have persistent hyperamylasemia of 
either isotype, pancreatic or salivary. Related to a moderate subclinical 
inflammatory progression.  
119
 
120
 
Inflammatory Bowel 
Disease 
Increased serum amylase after treatment of ulcerative colitis by azathioprine. 
Serum amylase was increased (149 U/L) but amylase was absent in the urine. 
This could potentially indicate the presence of macroamylasemia. Another 
case report showed similar results. 
 
121, 122
 
Renal Failure This may be due to a decreased clearance level of the kidneys. Hussein et al. 
thought that elevated serum amylase could be due to pancreatic damage due 
to reactive oxygen species. Renal failure increases the oxidative stress and 
inflammatory states of the pancreas.  
 
123, 124
 
Peptic Ulcer Motamedi et al. found salivary amylase activity to be increased, possibly 
because of oxidative stress from the peptic ulcers.  
 
125-127
 
Non-alcoholic Fatty 
Liver Disease 
Manifestation of a metabolic syndrome and insulin resistance. It has been 
shown to be related to low serum amylase levels independent of MetS, type 2 
diabetes, and obesity. 
 
23
 
Coeliac  Coeliac disease linked to hyperamylasemia and macroamylasemia 
24, 25
 
Familial 
Hyperamylasaemia 
Gullo et al. first described this condition from studying 18 patients who had 
increased amylase levels for a mean of 7.6 years. Two case studies were next 
to describe this condition in two young boys with abdominal pains and 
increased serum amylase. Both concluded it to be familial hyperamylasaemia 
and it to be autosomal dominant. 
 
128-130
 
 
 
Chronic Physiological 
Stress 
 
Increased serum amylase have been reported with increased stress, however, 
results are contended. 
131-134
 
 
 
Acute HIV A study of 94 HIV patients 7.5 (8%) patients have increased serum α-amylase 
pre-treatment, versus a study of 1368 HIV patients, 916.5 (67%) patients had 
increased serum α-amylase activity peri/post treatment, suggesting this 
increase is partially due to treatment options. Amylase activity may be as 
increased as 535 IU/L.  
 
135-138
 
 
 
Bacterial Infection Bacillus, Clostridium and Aeromonas spp. constitutively produce amylase.  
139, 140
 
 
*Variations in amylase activity with pancreatic disease are extensively discussed elsewhere.  
CFTR = Cystic Fibrosis Transmembrane Regulator. MetS = Metabolic syndrome 
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Supplementary material: State of the art in currently available amylase detection technique 
 
Assay Design Detection Limits of detection Specificity Ref. 
Sequential Process 
 
Technique 
  
Flow system using a 
peroxide electrode and 
enzyme membrane with 
glucose oxidase, α-
glucosidase and 
optionally mutarotase 
cross-linked by gelatin-
glutaraldehyde  
α-glucosidase 
converts maltose to 
α-D-glucose. 
Mutarotase 
converts α-D-
glucose to β-D-
glucose which is 
determined via 
glucose oxidase 
AMP LOD: 2nkat/mL 
(0.117.64 units/mL) 
when reaction time 
5 min 
0.5 nkat/mL 
(0.02941 units/mL) 
when reaction time 
30 min 
 
LR: 0.1-3 mmol/L 
Any α-
amylase 
141
 
Screen-printed 
electrodes with 
immobilized α-
glucosidase, glucose 
oxidase and mutarotase 
modified with Prussian 
Blue 
α-glucosidase 
converts maltose to 
α-D-glucose. 
Mutarotase 
converts α-D-
glucose to β-D-
glucose which is 
determined via 
glucose oxidase 
AMP LOD: 5 units/mL 
 
LR: 5-250 units/mL 
Any α-
amylase 
142
  
Flow-injection device 
using maltopentaose as 
substrate.  α-glucosidase 
immobilised on pre-
activated membrane. 
Glucose oxidase 
immobilized on 
electrode 
α-glucosidase 
converts maltose to 
5-d-glucose. 
Glucose oxidase 
coverts 5-d-glucose 
to gluconic acid and 
hydrogen peroxide 
which is measured 
AMP LOD: 
 
LR: 0-30 units/mL 
Any  α-
amylase 
143
 
Spectrophotometric flow 
injection measuring brick 
red complex formation 
at 540nm 
Amylose incubated 
with sample to 
produce maltose. 
3,5 dinitrosalicylic-
acid and maltose 
boiled  
SIA/FIA LOD: 0.0048 FAU 
LR: 0.005-0.06 FAU 
Any α-
amylase 
144
 
Use of portable personal 
glucose meter  
Sample, α-
glucosidase and 
maltopentaose 
incubated 15 min at 
37
0
C. 
 LOD: 20 U/L 
 
LR: 2.2-27.8 mM 
Any α-
amylase 
145
 
Flat-chip micro analytical 
sensor used as part of a 
Micro-Electro-
Mechanical Systems. 
Pre-column and flat-
enzyme electrode 
incorporated into a flow 
cell where maltose 
Maltose 
phosphorylase 
phosphorylates 
maltose. Glucose 
oxidase converts 
phosphorylated 
maltose  to 
gluconic acid and 
Electroche
mical and 
Lateral 
flow 
LR: 0-190 kU/L Any  α-
amylase 
143
 
Rate of product 
formation 
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phosphorylase, glucose 
oxidase and peroxidase 
immobilised 
hydrogen peroxide 
which is measured 
 Colorimetric assay 
biosensor system using 
Gal-G2-CNP, 
chromogenic substrate 
for α-amylase. CNP is a 
yellow product once 
hydrolysed which can be 
measured 
photometrically at 
430nm. 
Disposable test 
strip placed under 
tongue (25 µl). 
Once strip inserted 
into reader and 
saliva moved onto 
the reagent paper. 
The entire test 
takes roughly 30 
sec. 
AMP LR: 10-230 U/mL Any α-
amylase 
146
 
 
Flow injection 
spectrophotometric 
analysis based on starch-
iodine complexes 
Sample 
degradation of 
complexes 
measured in flow 
channel 
FIA LOD: 60 NU/mL 
LR: 0.25-5.0 
KNU/mL 
Any  α-
amylase 
147
 
Immobilized layer of 
starch gel on thick-film 
magneto elastic sensor 
and presence of  α-
amylase alters the 
resonance frequency  
Sample placed on 
starch gel 
 LR: 75-125 U/mL Any  α-
amylase 
148
 
Spectrofluorimetric 
using the quenching of 
luminescence intensity 
(634nm) of nano CdS 
doped in sol-gel of 
different concentrations 
of maltose 
Sample incubated 
with starch in flow 
channels 
FIA LOD: 5.7 x 10
-11 
mol/L 
 
LR: 4.8 x 10 
-10
 – 1.2 
x 10 
-5
 mol/L 
Any  α-
amylase 
149
 
Glycogen/amylopectin 
spin-coated on gold 
coated quartz crystals 
(case frequency of 10 
MHz). Films cross-linked 
with hexamethylene 
diisocyanate. Film 
degradation measured 
with quartz crystal 
microbalance 
Sample incubated 
with film  
EIS  Any  α-
amylase 
150
 
Degradation of starch-
triiodide measured using 
platinum redox sensor 
for direct potentiometric 
determination 
Sample incubated 
with starch-
triiodide 
 LOD: 1.944 mU 
 
LR: 0-0.54 U 
Any  α-
amylase 
151
 
 Glucose oxidase-based 
biosensor measuring the 
decrease in dissolved 
oxygen concentration 
related to starch 
concentration. 
  LOD: 
 
LR: 0.66-9.83 U/mL 
Any  α-
amylase 
152
 
Rate of starch digestion 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Glutaraldehyde as a 
cross-linker 
 
Layer of salivary 
antibody on Au-
electrode and 
interactions monitored 
by an electroactive 
indicator (K3Fe(CN)6). 
 
The electroactive 
was oxidized or 
reduced depending 
on concentration of 
salivary  α-amylase 
present 
AMP LOD: 1.57 pg/mL 
LR: 0.003-0.016 
ng/mL 
Human 
salivary  α-
amylase 
106
 
AMP = Amperometric, EIS = Electrochemical Impedance Spectroscopy, FAU = Fungal Amylase Unit, FIA = Flow 
Injection Analysis, KNU = kilo Novo unit, LOD = Limit of Detection, LR = Linear Range, nkat = nanokatals 
 
 
 
 
 
 
References: 
1.  Fife CE, Carter MJ, Walker D, Thomson B. Wound care outcomes and associated cost among 
patients treated in US outpatient wound centers: data from the US wound registry. Wounds. 
2012;24:10-7. 
2.  Azzopardi EA, Azzopardi E, Camilleri L, Villapalos J, Boyce DE, Dziewulski P, et al. Gram Negative 
Wound Infection in Hospitalised Adult Burn Patients-Systematic Review and Metanalysis. PloS 
one. 2014;9:e95042. 
3.  Azzopardi EA, Ferguson EL, Thomas DW. Colistin past and future: A bibliographic analysis. 
Journal of Critical Care. 2013;28:219. e13-. e19. 
4.  Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no 
ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1-
12. 
5.  Worldwide Cancer Key Stats.  Key Stats. CancerStats: Cancer Research UK; 2014. 
6.  Spellberg B, Bartlett J, Gilbert D. The Future of Antibiotics and Resistance. The New England 
Journal of Medicine. 2013;368:299-302. 
7.  Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher H, Scheld W, et al. The Epidemic of 
Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious 
Diseases Society of America. Clinical Infectious Diseases. 2008;46:155-64. 
8.  Antimicrobial Resistance: A Problem Without Borders. The Richard & Hinda Rosenthal 
Symposium 2014. 2014:46. 
9.  Friedberg F. The remarkable amylases. Biochemical Education. 1985;13:105-7. 
10.  Steinberg W, DeVries JH, Wadden TA, Jensen CB, Svendsen CB, Rosenstock J. Tu1502 
Longitudinal Monitoring of Lipase and Amylase in Adults With Type 2 Diabetes and Obesity: 
Evidence From Two Phase 3 Randomized Clinical Trials With the Once-Daily GLP-1 Analog 
Liraglutide. Gastroenterology. 2012;142:S-850. 
Antibody to antigen 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11.  Seetharaman K, Bertoft E. Perspectives on the history of research on starch Part II: On the 
discovery of the constitution of diastase. Starch‐Stärke. 2012;64:765-9. 
12.  National Library of Medicine. MeSH Browser. 
. 2009. 
13.  MacGregor E, Janecek S, Svensson B. Relationship of Sequence and Structure to Specificity in the 
α-amylase Family of Enzymes. Protein Structure and Molecular Enzymology. 2001;1546:1-20. 
14.  Miyake H, Kurisu G, Kusunoki M, Nishimura S, Kitamura S, Nitta Y. Crystal Structure of a Catalytic 
Site Mutant of Beta-amylase from Bacillus Cereus Var. Mycoides Cocrystallized with 
Maltopentaose. Biochemsitry. 2003;42:5574-81. 
15.  Henrissat B. A Classification of Glycosyl Hydrolases based on Amino Acid Sequence Similarites. 
Biochemistry Journal. 1991;280:309-16. 
16.  Janecek S, Svensson B, MacGregor A. α-Amylase: an Enzyme Specificity Found in Various 
Families of Glycoside Hydrolases. Cellular and Molecular Life Sciences. 2014;71:1149-70. 
17.  Ferey-Roux G, Perrier J, Forest E, Marchie-Mouren G, Puigserver A, Santimone M. The Human α-
amylase Isoforms: Isolation, Structural Studies and Kinetics of Inhibition by Acarbose. Protein 
Structure and Molecular Enzymology. 1998;1388:10-20. 
18.  Whitcomb D, Lowe M. Human Pancreatic Digestive Enzymes. Digestive Diseases and Sciences. 
2007;52:1-17. 
19.  Brayer G, Luo Y, Withers S. The Structure of Human Pancreatic Alpha-amylase at 1.8 A 
Resolution and Comparisons with Related Enzymes. Protein Science. 1995;4:1730-42. 
20.  Vipin AK, Hu B, Fugetsu B. Prussian blue caged in alginate/calcium beads as adsorbents for 
removal of cesium ions from contaminated water. Journal of hazardous materials. 2013;258:93-
101. 
21.  Horsman SR, Moore RA, Lewenza S. Calcium chelation by alginate activates the type III secretion 
system in mucoid Pseudomonas aeruginosa biofilms. 2012. 
22.  Worthington Inc. Effect of pH on amylase. 2015. 
23.  Nakajima K, Oshida H, Muneyuki T, Saito M, Hori Y, Fuchigami H, et al. Independent Association 
between Low Serum Amylase and Non-Alcoholic Fatty Liver Disease in Asymptomatic Adults: a 
Cross-Sectional Observational Study. BMJ Open. 2013;3:e002235. 
24.  Depsames R, Fireman Z, Niv E, Kopelman Y. Macromylasemia as the First Manifestation of Celiac 
Disease. Case Reports in Gastroenterology. 2008;2:196-8. 
25.  Liu Z, Wang J, Qian J, Tang F. Hyperamylasemia, Reactive Plasmacytosis, and Immune 
Abnormalities in a Patient with Celiac Disease. Digestive Diseases and Sciences. 2007;52:1444-7. 
26.  Venkataraman D, Howarth L, Beattie R, Afzal A. A Very High Amylase can be Benign in Paediatric 
Crohn's Disease. BMJ Case Reports. 2012. 
27.  Rosenblum J. Serum Lipase Activity is Increased in Disease States other than Acute Pancreatitis: 
Amylase Revisited. Clinical Chemistry. 1991;37:315-6. 
28.  Azzopardi EA, Ferguson EL, Thomas DW. The Enhanced Permeability Retention Effect: A New 
Paradigm for Drug Targeting in Infection. Journal of Antimicrobial Chemotherapy. 2012;In Press. 
29.  Ferguson E, Walsh T, Thomas D. Therapeutic conjugates. GB 1010500.5, PCT/GB2011/051029, 
WO/2012/035310. UK 2012. 
30.  Azzopardi E, Ferguson E, Thomas D. Polymer therapeutics for effective antimicrobial targeting in 
burn injury.  BRITISH JOURNAL OF SURGERY: WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN 
ST, MALDEN 02148, MA USA; 2011. p. 55-. 
31.  Azzopardi EA, Ferguson EL, Thomas DW. Development and Validation of an In Vitro 
Pharmacokinetic/Pharmacodynamic Model To Test the Antibacterial Efficacy of Antibiotic 
Polymer Conjugates. Antimicrobial agents and chemotherapy. 2015;59:1837-43. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
32.  Shelley WB, Mescon H. Histochemical demonstration of secretory activity in human eccrine 
sweat glands. J Invest Dermat. 1952;18:289-301. 
33.  Eguchi T, Ishikawa Y, Ishida H. Mechanism Underlying Histamine-induced Densenitization of 
Amylase Secretion in Rat Parotid Glands. British Journal of Pharmacology. 1998;124:1523-33. 
34.  Francis T, Graf A, Hodges K, Kennedy L, Hargrove L, Price M, et al. Histamine Regulation of 
Pancreatitis and Pancreatic Cancer: A Review of Recent Findings. Hepatobiliary Surgery and 
Nutrition. 2013;2:216-26. 
35.  MacGlashan D. Histamine: A mediator of Inflammation. American Academy of Allergy, Asthma 
and Immunology. 2003:s53-s9. 
36.  Couto S, Sanroman M. Application of solid-state fermentation to food industry—a review. 
Journal of Food Engineering. Journal of Food Engineering. 2006;76:291-302. 
37.  Snoeijers S, Perez-Garcia A, Joosten M, De Wit P. The effect of nitrogen on disease development 
and gene expression in bacterial and fungal plant pathogens. European Journal of Plant 
Pathology. 2000;106:493-506. 
38.  Yavankar S, Pardesi K, Chopade B. Species Distribution and Physiological Characterization of 
Acinetobacter Genospecies from Healthy Human Skin of Tribal Population in India. Indian 
Journal of Medical Microbiology. 2007;25:336-45. 
39.  Khannous L, Jrad M, Dammak M, Miladi R, Chaaben N, Khemakhem B, et al. Isolation of a Novel 
Amylase and Lipase-producing Pseudomonas luteola Strain: Study of Amylase Production 
Conditions. Lipids Health and Disease. 2014;13. 
40.  Rasiah I, Rehm B. One-step Production of Immobilized Alpha-amylase in Recombinant 
Escherichia coli. Applied Environmental Microbiology. 2009;75:2012-6. 
41.  Pohl S, Harwood C. Chapter 1 - Heterologous Protein Secretion by Bacillus Species: From the 
Cradle to the Grave. Advances in Applied Microbiology. 2010;73:1-25. 
42.  Urbina P, Collado MI, Alonso A, Goni FM, Flores-Diaz M, Alape-Giron A, et al. Unexpected wide 
substrate specificity of C. perfringens alpha-toxin phospholipase C. Biochimica et biophysica 
acta. 2011;1808:2618-27. 
43.  Brook I. Current concepts in the management of Clostridium tetani infection. Expert review of 
anti-infective therapy. 2008;6:327-36. 
44.  Vidor C, Awad M, Lyras D. Antibiotic resistance, virulence factors and genetics of Clostridium 
sordellii. Research in microbiology. 2014. 
45.  Goudarzi M, Seyedjavadi SS, Goudarzi H, Mehdizadeh Aghdam E, Nazeri S. Clostridium difficile 
Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options. Scientifica. 
2014;2014:916826. 
46.  Sharma SK, Basavanna U, Shukla HD. Protein Domain Analysis of C. botulinum Type A 
Neurotoxin and Its Relationship with Other Botulinum Serotypes. Toxins. 2010;2:1-9. 
47.  Sarvas M, Harwood C, Bron S, Diji J. Post-translocational Folding of Secretory Proteins in Gram-
positive Bacteria. Molecular Cell Research. 2004;1694:311-27. 
48.  Chen E, Deng L, Liu Z, Zhu X, Chen X, Tang H. Management of gas gangrene in Wenchuan 
earthquake victims. J Huazhong Univ Sci Technol [Med Sci]. 2011;31:83-7. 
49.  Pettitt DA, Molajo A, McArthur P. A human bite. BMJ. 2012;345. 
50.  Bakker DJ. Clostridial myonecrosis (gas gangrene). Undersea and Hyperbaric Medicine. 
2012;39:731. 
51.  Weinstein L, Barza MA. Gas gangrene. The New England journal of medicine. 1973;289:1129. 
52.  Permpoonpattana P, Hong H, Khaneja R, Cutting S. Evaluation of Bacillus subtilis strains as 
probiotics and their potential as a food ingredient. Beneficial microbes. 2012;3:127-35. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
53.  Soni SK, Goyal N, Gupta JK, Soni R. Enhanced production of α‐amylase from Bacillus subtilis 
subsp. spizizenii in solid state fermentation by response surface methodology and its evaluation 
in the hydrolysis of raw potato starch. Starch‐Stärke. 2012;64:64-77. 
54.  Emele FE. Rapid iodometric detection of Aeromonas amylase and its diagnostic significance. 
Diagnostic Microbiology and Infectious Disease.40:91-4. 
55.  Gurung N, Ray S, Bose S, Rai V. A broader view: microbial enzymes and their relevance in 
industries, medicine, and beyond. BioMed research international. 2013;2013. 
56.  Whitaker IS, Oboumarzouk O, Rozen WM, Naderi N, Balasubramanian S, Azzopardi EA, et al. The 
efficacy of medicinal leeches in plastic and reconstructive surgery: a systematic review of 277 
reported clinical cases. Microsurgery. 2012;32:240-50. 
57.  Azzopardi EA, Azzopardi SM, Boyce DE, Dickson WA. Emerging gram-negative infections in burn 
wounds. Journal of Burn Care & Research. 2011;32:570-6. 
58.  Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. Journal 
of Controlled Release. 2012;164:138-44. 
59.  Fong J, Ferraro DJ, Hunn J, Roberts S, Berezin MY, Rogers BE, et al. Radiation increases 
permeability and retention of PEG-conjugates in solid tumors. Cancer Research. 2013;73:2666-. 
60.  Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends in 
biotechnology. 2006;24:39-47. 
61.  Brown CB, Luciano AA, Martin D, Peers E, Scrimgeour A, Group AARS. Adept (icodextrin 4% 
solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, 
randomized, controlled study. Fertility and sterility. 2007;88:1413-26. 
62.  Barenholz YC. Doxil®—the first FDA-approved nano-drug: lessons learned. Journal of Controlled 
Release. 2012;160:117-34. 
63.  Federal Drug Agency. FDA approved drug products-icodextrin. 2010. 
64.  Guo A, Wolfson M, Holt R. Early quality of life benefits of icodextrin in peritoneal dialysis. Kidney 
International. 2002;62:S72-S9. 
65.  Woolfson A, Ricketts C, Hardy S, Saour J, Pollard B, Allision S. Prolonged nasogastric tube feeding 
in critically ill and surgical patients. . Postgraduate Medical Journal. 1976; 52. 
66.  Davies SJ. Exploring new evidence of the clinical benefits of icodextrin solutions. Nephrology 
Dialysis Transplantation. 2006;21 Suppl 2:ii47-50. 
67.  Kerr D, Young A, Neoptolemos J, Sherman M, Van-Geene P, Stanley A, et al. Prolonged 
intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. British journal of cancer. 
1996;74:2032. 
68.  Peers E, Gokal R. Icodextrin provides long dwell peritoneal dialysis and maintenance of 
intraperitoneal volume. Artificial organs. 2008;22:8-12. 
69.  Boury B, Plumejeau S. Metal oxides and polysaccharides: an efficient hybrid association for 
materials chemistry. Green Chemistry. 2015;17:72-88. 
70.  Riva FM, Chen YC, Tan NC, Lin PY, Tsai YT, Chang HW, et al. The outcome of prostaglandin‐E1 
and dextran‐40 compared to no antithrombotic therapy in head and neck free tissue transfer: 
Analysis of 1,351 cases in a single center. Microsurgery. 2012;32:339-43. 
71.  Burkart J. Metabolic consequences of peritoneal dialysis. . Seminars in Dialysis. 2004; 6. 
72.  Davies DS. Kinetics of icodextrin. Perit Dial Int. 1993;14:S45-S50. 
73.  Roberts P, Whelan W. The mechanism of carboydrase action. Biochemistry Journal 1960;76. 
74.  Duncan R, Gaspar R. Nanomedicine (s) under the Microscope. Molecular Pharmaceutics. 
2011;8:2101-41. 
75.  Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Current Opinion in 
Biotechnology. 2011;22:492-501. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
76.  Azzopardi EA, Camilleri L, Moseley R, Thomas DW, Ferguson EL. Statistical characterization of 
succinoylated dextrin degradation behavior in human α-amylase. Journal of Carbohydrate 
Chemistry. 2013;32:438-49. 
77.  Azzopardi E, Ferguson E, Thomas D. A novel class of bioreponsive nanomedicines for localised 
reinstatement of bioactivity and specific targeting. The Lancet. 2014;383:S9. 
78.  Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. 
Advanced drug delivery reviews. 2013;65:60-70. 
79.  Duncan R, Gaspar R. Nanomedicine (s) under the Microscope. Molecular Pharmaceutics. 2011. 
80.  Ferguson EL, Azzopardi E, Roberts JL, Walsh TR, Thomas DW. Dextrin–colistin conjugates as a 
model bioresponsive treatment for multidrug resistant bacterial infections. Molecular 
Pharmaceutics. 2014;11:4437-47. 
81.  Duncan R, Gilbert H, Carbajo R, Vicent M. Polymer Masked-Unmasked Protein Therapy. 1. 
Bioresponsive Dextrin- Trypsin and -Melanocyte Stimulating Hormone Conjugates Designed 
for α-amylase Activation. Biomacromolecules. 2008;9:1146-54. 
82.  Duncan R, Gilbert H, Carbajo R, Vicent M. Polymer Masked- Unmasked Protein Therapy. 1. 
Bioresponsive Dextrin- Trypsin and- Melanocyte Stimulating Hormone Conjugates Designed for -
Amylase Activation. Biomacromolecules. 2008;9:1146-54. 
83.  Hardwicke J, Ferguson E, Moseley R, Stephens P, Thomas D, Duncan R. Dextrin-rhEGF 
Conjugates as Bioresponsive Nanomedicines for Wound Repair. Journal of Controlled Release. 
2008;130:275-83. 
84.  Ferguson EL, Azzopardi E, Roberts JL, Walsh TR, Thomas DW. Dextrin-colistin conjugates as a 
model bioresponsive treatment for multidrug resistant bacterial infections. Mol Pharm. 
2014;11:4437-47. 
85.  Azzopardi EA, Ferguson EL, Thomas DW. Development and Validation of an In Vitro 
Pharmacokinetic/Pharmacodynamic Model to Test the Antibacterial Efficacy of Antibiotic 
Polymer Conjugates. Antimicrobial agents and chemotherapy. 2014:AAC. 03708-14. 
86.  Hardwicke J, Moseley R, Stephens P, Harding K, Duncan R, Thomas D. Bioresponsive Dextrin-
rhEGF Conjugates: In Vitro Evaluation in Models Relevant to its Proposed Use as a Treatment for 
Chronic Wounds. Molecular Pharmaceuticals. 2010;7:699-707. 
87.  Ferguson E, Duncan R. Dextrin-Phospholipase A2: Synthesis and Evalution as a Bioresponsive 
Anticancer Conjugate. Biomacromolecules. 2009;10:1358-64. 
88.  Marcinow AM, Hall N, Byrum E, Teknos TN, Old MO, Agrawal A. Use of a novel receptor-targeted 
(CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in 
oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study. 
JAMA Otolaryngology–Head & Neck Surgery. 2013;139:895-902. 
89.  Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, et al. Combined analysis of Phase 
III trials evaluating [99mTc] Tilmanocept and vital blue dye for identification of sentinel lymph 
nodes in clinically node-negative cutaneous melanoma. Annals of surgical oncology. 
2013;20:680-8. 
90.  Greco F, Vicent MJ. Polymer-drug conjugates: current status and future trends. Frontiers in 
Bioscience. 2008:2744-56. 
91.  Sommermeyer K, Eichner W. Haemoglobin-hydroxyethyl starch conjugates as oxygen carriers. 
Google Patents; 2000. 
92.  Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl 
starch 130/0.42 versus Ringer's acetate in severe sepsis. New England Journal of Medicine. 
2012;367:124-34. 
93.  Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl starch or saline for 
fluid resuscitation in intensive care. New England Journal of Medicine. 2012;367:1901-11. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
94.  Ferguson EL, Duncan R. Dextrin-phospholipase A2: synthesis and evaluation as a bioresponsive 
anticancer conjugate. Biomacromolecules. 2009;10:1358-64. 
95.  Li L, Somerset S. Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy. 
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the 
Italian Association for the Study of the Liver. 2014;46:865-74. 
96.  Somaraju UR, Solis-Moya A. Pancreatic enzyme replacement therapy for people with cystic 
fibrosis. The Cochrane database of systematic reviews. 2014;10:CD008227. 
97.  Sales PM, Souza PM, Simeoni LA, Silveira D. alpha-Amylase inhibitors: a review of raw material 
and isolated compounds from plant source. Journal of pharmacy & pharmaceutical sciences : a 
publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des 
sciences pharmaceutiques. 2012;15:141-83. 
98.  de Sales P, de Souza P, Simeoni L, Magalhaes P, Silveira D. α-amylase Inhibitors: A Review of Raw 
Material and Isolated Compounds from Plant Source. Journal of Pharmacy and Pharmaceutical 
Sciences. 2012;15:141-83. 
99.  de Gouveia N, Alves F, Furtado F, Scherer D, Mundim A, Espindola F. An In Vitro and In Vivo 
Study of the α-amylase Activity of Phaseolamin. Journal of Medicinal Food. 2014;17:915-20. 
100.  Oliveira R, Oliveira V, Deconte S, Calabria L, Silva Moraes A, Espindola F. Phaseolamin Treatment 
Prevents Oxidative Stress and Collagen Deposition in the Hearts of Streptozotocin-induced 
Diabetic Rates. Diabetic Vascular Disease Research. 2014;11:110-7. 
101.  Candido G, Ton S, Alfenas G. Addition of Dietary Fiber Sources to Shakes Reduces Postprandial 
Glycemia and Alters Food Intake. Nutricion Hospitalaria. 2014;31:299-306. 
102.  Mendez M, Goni A, Ramirez W, Grau R. Sugar inhibits the production of the toxins that trigger 
clostridial gas gangrene. Microbial pathogenesis. 2012;52:85-91. 
103.  Maeda E, Kataoka M, Yatsushiro S, Kajimoto K, Hino M, Kaji N, et al. Accurate quantitation of 
salivary and pancreatic amylase activities in human plasma by microchip electrophoretic 
separation of the substrates and hydrolysates coupled with immunoinhibition. Electrophoresis. 
2008;29:1902-9. 
104.  Morishita Y, Iinuma Y, Nakashima N, Majima K, Mizuguchi K, Kawamura Y. Total and pancreatic 
amylase measured with 2-chloro-4-nitrophenyl-4-O-beta-D-galactopyranosylmaltoside. Clin 
Chem. 2000;46:928-33. 
105.  Perich C, Ricós C, Alvarez V, Biosca C, Boned B, Cava F, et al. External quality assurance programs 
as a tool for verifying standardization of measurement procedures: Pilot collaboration in Europe. 
Clinica Chimica Acta. 2014;432:82-9. 
106.  Aluoch AO, Sadik OA, Bedi G. Development of an oral biosensor for salivary amylase using a 
monodispersed silver for signal amplification. Analytical biochemistry. 2005;340:136-44. 
107.  Wu S, Zhu Y, Cai Q, Zeng K, Grimes C. A Wireless Magnetoelastic α-amylase Sensor. Sensors and 
Activators B. 2007;121:467-81. 
108.  Weitgasser R, Gappmayer B, Pichler M. Newer portable glucose meters—analytical 
improvement compared with previous generation devices? Clinical Chemistry. 1999;45:1821-5. 
109.  Meisler MH, Ting C-N. The remarkable evolutionary history of the human amylase genes. Critical 
Reviews in Oral Biology & Medicine. 1993;4:503-9. 
110.  Ragunath C, Manuel S, Venkataraman V, Sait H, Kashinathan C, Ramasubbu N. Probing the Role 
of Aromatic Residues at the Secondary Saccharide-Binding Sites of Human Salivary Alpha-
amylase in Substrate Hydrolysis and Bacterial Binding. Journal of Molecular Biology. 
2008;384:1232-48. 
111.  Fisher SZ, Govindasamy L, Tu C, Agbandje-McKenna M, Silverman DN, Rajaniemi HJ, et al. 
Structure of human salivary alpha-amylase crystallized in a C-centered monoclinic space group. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Acta crystallographica Section F, Structural biology and crystallization communications. 
2006;62:88-93. 
112.  Ramasubbu N, Ragunath C, Mishra P, Thomas L, Gyemant G, Kandra L. Human Salivary α-
amylase Trp58 Situated at Subsite -2 is Critical for Enzyme Activity European Journal of 
Biochemistry. 2004;271:2517-29. 
113.  Henrissat B, Bairoch A. New Families in the Classification of Glycosyl Hydrolases Based on Amino 
Acid Sequence Similarites. Biochemistry Journal. 1993;293:781-8. 
114.  Henrissat B, Romeu A. Families, Superfamilies and Subfamilies of Glycosyl Hydrolases. 
Biochemistry Journal. 1995;311:350-1. 
115.  Henrissat B, Bairoch A. Updating the Sequence-Based Classification of Glycosyl Hydrolases. 
Biochemistry Journal. 1996;316:695-6. 
116.  Cantarel B, Coutinho P, Rancurel C, Bernard T, Lombard V, Henrissat B. The Carbohydrate-Active 
EnZymes Database (CAZy): an Expert Resource for Glycogenomics. Nucleic Acids Research. 
2009;37:D233-D8. 
117.  Lombard V, Ramulu H, Drula E, Coutinho P, Henrissat B. The Carbohydrate-Active Enzymes 
Database (CAZy) in 2013. Nucleic Acids Research. 2014;42:D490-D5. 
118.  Steinberg W, Nauck M, Zinman B, Daniels G, Bergenstal R, Mann J, et al. LEADER 3 - Lipase and 
Amylase Activity in Subjects With Type 2 Diabetes. Pancreas. 2014;43:1223-31. 
119.  Hernandez-Molina G, Michel-Peregrina M. Sjögren's Syndrome and Pancreatic Affection. 
Reumatologia Clinica. 2011;7:130-4. 
120.  Kaneko H, Ohkawara Y, Taniguchi K, Matsumoto Y, Nomura K, Horiike S, et al. Simultaneous 
Complication of Multiple Myeloma with Sögren Syndrome. Asian Pacific Journal of Allergy and 
Immunology. 2006;24:245-8. 
121.  Liverani E, Leonardi F, Castellani L, Cardamone C, Belluzzi A. Asymptomatic and Persistent 
Elevation of Pancreatic Enzymes in an Ulcerative Colitis Patient. Case Report Gastrointestinal 
Medicines. 2013;2013:415619. 
122.  Kum F, Gulati A, Hussain A. Hyperamylasaemia and Ischaemic Colitis. International Journal of 
Surgery - Case Report. 2014;5:63-6. 
123.  Khan F, Al-Ani A, Ali H. Typhoid Rhabdomyolysis with Acute Renal Failure and Acute Pancreatitis: 
a Case Report and Review of the Literature. International Journal of Infectious Diseases. 
2009;13:e282-e5. 
124.  Hussein A, Abd-Elkhabir A, Abozahra A, Baiomy A, Ashamallah S, Sheashaa H, et al. Pancreatic 
Injury Secondary to Renal Ischemia/Reperfusion (I/R) Injury: Possible Role of Oxidative Stress. 
Physiology Research. 2014;63:47-55. 
125.  Motamedi M, Mansour-Ghanaei F, Sariri R, Vesal M. Salivary Enzymes in Peptic Ulcer Disease. 
Journal of Oral Biology and Craniofacial Research. 2013;3:83-7. 
126.  Lee K, Paik C, Chung W, Yang J. Association Between Acute Pancreatitis and Peptic Ulcer Disease. 
World Journal of Gastroenterology. 2011;17:1058-62. 
127.  Lin C, Wang Z, Lai K, Lo G, Hsu P. Gastrointestinal Mucosal Lesions in Patients with Acute 
Pancreatitis. Chinese Medical Journal. 2002;65:275-8. 
128.  Gullo L. Chronic Nonpathological Hyperamylasemia of Pancreatic Origin. Gastroenterology. 
1996;110:1905-8. 
129.  Koda YKL, Vidolin E. Familial Hyperamylasemia. Revista do Hospital das Clinicas. 2002;54:77-82. 
130.  Cuckow P, Foo A, Jamal A, Stringer M. Familial Hyperamylasaemia. Gut. 1997;40:689-90. 
131.  Vineetha R, Keerthilatha-M P, Vengal M, Kodyalamoole G, Narayanakurup D. Usefulness of 
Salivary Alpha Amylase as a Biomarker of Chronic Stress and Stress Related Oral Mucosal 
Changes - a Pilot Study. Journal of Clinical and Experimental Dentistry. 2014;6:e132-e7. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
132.  Allwood M, Handwerger K, Kivlighan K, Granger D, Stroud L. Direct and Moderating Links of 
Salivary Alpha-Amylase and Cortisol Stress-Reactivity to Youth Behavioral and Emotional 
Adjustment. Biological Psychology. 2011;88:57-64. 
133.  Koh D, Ng V, Naing L. Alpha Amylase as a Salivary Biomarker of Acute Stress of Venepuncture 
from Periodic Medical Examinations. Front Public Health. 2014;2:1-5. 
134.  Laurent H, Powers S, Granger D. Refining the Multisytem View of the Stress Response: 
Coordination Among Cortisol, Alpha-Amylase, and Subjective Stress in Response to Relationship 
Conflict. Physiology and Behavior. 2013;119:52-60. 
135.  Moore J, Schneider S. Acute Human Immunodeficiency Virus (HIV) Infection Presenting with 
Fever, Elevated Amylase/Lipase, and Hematologic Abnormalities. Journal of Emergency 
Medicine. 2013;44:e341-e4. 
136.  Moolla Z, Anderson F, Thomson S. Use of Amylase and Alanine Transaminase to Predict Acute 
Gallstone Pancreatitis in a Population with High HIV Prevalence. World Journal of Surgery. 
2012;37:156-1661. 
137.  Lambertus M, Anderson R. Hyperamylasemia in Patients with Human Immunodeficiency Virus 
Infection. The New England Journal of Medicine. 1990;323:1708-9. 
138.  Ryan R, Dayaram Y, Schaible D, Coate B, Anderson D. Outcomes in Older Versus Younger 
Patients Over 96 Weeks in HIV-1- Infected Patients Treated with Rilpivirine or Efavirenz in ECHO 
and THRIVES. Current HIV Research. 2013;11:570-5. 
139.  Nanmori T, Nagai M, Shimizu Y, Shinke R, Mikami B. Cloning of the beta-amylase gene from 
Bacillus cereus and characteristics of the primary structure of the enzyme. Applied and 
environmental microbiology. 1993;59:623-7. 
140.  Sylvestre P, Moya M, Haustant M, Vaissaire J, Mock M. Carbohydrate Metabolism Differences 
between Subgroup A1 and B2 Strains of Bacillus anthracis as Assessed by Comparative Genomics 
and Functional Genetics. Applied and environmental microbiology. 2009;75:5727-8. 
141.  Zajoncova L, Jilek M, Beranova V, Pec P. A biosensor for the determination of amylase activity. 
Biosensors & bioelectronics. 2004;20:240-5. 
142.  Mahosenaho M, Caprio F, L. M, Sesay A, Palleschi G, Virtanen V. A Disposable Biosensor for the 
Determination of Alpha-amylase in Human Saliva. Microchimica Acta. 2010;170:243-9. 
143.  Yamaguchi M, Deguchi M, Wakasugi J. Flat-chip microanalytical enzyme sensor for salivary 
amylase activity. Biomedical microdevices. 2005;7:295-300. 
144.  Staden J, Mulaudzi. Flow Injection Spectrophotometric Assay of α-amylase Activity. Analytica 
Chimica Acta. 2000;421:19-25. 
145.  Wang Q, Wang H, Yang X, Wang K, Liu R, Li Q, et al. A sensitive one-step method for quantitative 
detection of alpha-amylase in serum and urine using a personal glucose meter. The Analyst. 
2014. 
146.  Shetty V, Zigler C, Robles TF, Elashoff D, Yamaguchi M. Developmental validation of a point-of-
care, salivary alpha-amylase biosensor. Psychoneuroendocrinology. 2011;36:193-9. 
147.  Ohtomo T, Igarashi S, Takagai Y. Flow injection spectrophotometric analysis of human salivary 
alpha-amylase activity using an enzyme degradation of starch-iodine complexes in flow channel 
and its application to human stress testing. Biological & pharmaceutical bulletin. 2013;36:1857-
61. 
148.  Wu S, Zhu Y, Cai Q, Zeng K, Grimes C. A wireless magnetoelastic α-amylase sensor. Sensors and 
Actuators B: Chemical. 2007;121:476-81. 
149.  Attia MS, Zoulghena H, Abdel-Mottaleb MS. A new nano-optical sensor thin film cadmium 
sulfide doped in sol-gel matrix for assessment of alpha-amylase activity in human saliva. The 
Analyst. 2014;139:793-800. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
150.  Gibbs MJ, Biela A, Krause S. alpha-Amylase sensor based on the degradation of oligosaccharide 
hydrogel films monitored with a quartz crystal sensor. Biosensors & bioelectronics. 2014. 
151.  Sakac N, Sak-Bosnar M, Horvat M, Madunic-Cacic D, Szechenyi A, Kovacs B. A new 
potentiometric sensor for the determination of alpha-amylase activity. Talanta. 2011;83:1606-
12. 
152.  Altug C, Mengulluoglu U, Kurt E, Kaya S, Dinckaya E. A novel biosensor based on glucose oxidase 
for activity determination of alpha - amylase. Artificial cells, blood substitutes, and 
immobilization biotechnology. 2011;39:298-303. 
  
  
